98 related articles for article (PubMed ID: 23291071)
1. [A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
Wu SK; Ma Y; Meng XY; Sun B; Wang T; Zhang SH; Jiang ZF; Song ST
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):764-9. PubMed ID: 23291071
[TBL] [Abstract][Full Text] [Related]
2. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab based chemotherapy in first line treatment of HER2 negative metastatic breast cancer: results of a Moroccan observational institutional study.
Boulaamane L; Boutayeb S; Errihani H
BMC Res Notes; 2012 Mar; 5():162. PubMed ID: 22439740
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of weekly paclitaxel in patients with docetaxel-resistant metastatic breast cancer.
Yonemori K; Katsumata N; Uno H; Matsumoto K; Kouno T; Tokunaga S; Yamanaka Y; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2005 Feb; 89(3):237-41. PubMed ID: 15754121
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Baur M; van Oosterom AT; Diéras V; Tubiana-Hulin M; Coombes RC; Hatschek T; Murawsky M; Klink-Alakl M; Hudec M; Dittrich C
J Cancer Res Clin Oncol; 2008 Feb; 134(2):125-35. PubMed ID: 17636328
[TBL] [Abstract][Full Text] [Related]
6. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of docetaxel combined capecitabine on metastatic breast cancer].
Wang XX; Zhou ZM; Yuan ZY; Zhang DS; Shi YX; Jiang WQ
Ai Zheng; 2007 Apr; 26(4):407-10. PubMed ID: 17430662
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer.
Salem DA; Gado NM; Abdelaziz NN; Essa AE; Abdelhafeez ZM; Kamel TH
J Egypt Natl Canc Inst; 2008 Jun; 20(2):134-40. PubMed ID: 20029469
[TBL] [Abstract][Full Text] [Related]
10. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
11. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of docetaxel for anthracycline-resistant metastatic breast cancer].
Ikeda H; Koshiba R
Gan To Kagaku Ryoho; 2001 May; 28(5):637-41. PubMed ID: 11383211
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer].
Zhou NN; Lin XB; Liu DG; Teng XY; Zhong JT; Jiang WQ
Ai Zheng; 2008 Sep; 27(9):947-50. PubMed ID: 18799033
[TBL] [Abstract][Full Text] [Related]
15. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
[TBL] [Abstract][Full Text] [Related]
16. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose finding study evaluating the combination of bendamustine with weekly paclitaxel in patients with pre-treated metastatic breast cancer: RiTa trial.
Loibl S; Murmann C; Schwedler K; Warm M; Müller L; Heinrich G; Nekljudova V; von Minckwitz G
Cancer Chemother Pharmacol; 2009 Apr; 63(5):953-8. PubMed ID: 18716777
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel monotherapy as a second-line treatment after failure of fluoropyrimidine and platinum in advanced gastric cancer: experience of 154 patients with prognostic factor analysis.
Jo JC; Lee JL; Ryu MH; Sym SJ; Lee SS; Chang HM; Kim TW; Lee JS; Kang YK
Jpn J Clin Oncol; 2007 Dec; 37(12):936-41. PubMed ID: 18211985
[TBL] [Abstract][Full Text] [Related]
19. Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial.
Schmid P; Krocker J; Kreienberg R; Klare P; Kittel K; Sommer H; Heinrich G; Steck T; Lichtenegger W; Elling D; Kümmel S
Cancer Chemother Pharmacol; 2009 Jul; 64(2):401-6. PubMed ID: 19104816
[TBL] [Abstract][Full Text] [Related]
20. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study.
Stathopoulos GP; Tsavdaridis D; Malamos NA; Rigatos SK; Kosmas Ch; Pergantas N; Stathopoulos JG; Xynotroulas J
Cancer Chemother Pharmacol; 2005 Nov; 56(5):487-91. PubMed ID: 15868147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
